Financial Highlights
Financial Highlights
Boehringer Ingelheim Group of companies
Financial Highlights
Financial Highlights
| Boehringer Ingelheim group of companies | 2015 | 2014 | Change |
|---|---|---|---|
| Net sales | 14,798 | 13,317 | 11% |
| Net sales by region | |||
| Europe | 28% | 31% | |
| Americas | 47% | 44% | |
| Asia, Australia, Africa | 25% | 25% | |
| by business | |||
| Prescription Medicines | 76% | 76% | |
| Consumer Health Care | 10% | 11% | |
| Animal Health | 9% | 8% | |
| Biopharmaceuticals | 4% | 4% | |
| Industrial Customers and other sales | 1% | 1% | |
| Research and Development | 3,004 | 2,654 | +13% |
| Personnel costs | 4,518 | 4,116 | +10% |
| Average number of employees | 47,501 | 47,743 | -1% |
| Operating income | 2,269 | 2,140 | +6% |
| Operating income as % of net sales | 15.3% | 16.1% | |
| Income after taxes | 1,577 | 1,047 | +51% |
| Income after taxes as % of net sales | 10.7% | 7.9% | |
| Shareholders' equity | 9,603 | 8,111 | +18% |
| Return on shareholders' equity | 19.4% | 14.7% | |
| Cash flow | 2,605 | 1,850 | +41% |
| Investments in tangible assets | 591 | 548 | +8% |
| Depreciation of tangible assets | 475 | 449 | +6% |